Pharmaceutical Executive September 11, 2024
A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.
In the current obesity drug market, GLP-1 agonists manufactured by Novo Nordisk and Eli Lilly have garnered the majority of the attention. Currently, the two companies hold a combined 68% of sales from weight-loss drugs, however, new entrants are set to challenge their market share, according to a report by Morningstar. Biopharma companies such as Roche, Amgen, Pfizer, and AstraZeneca are currently developing obesity drugs of their own, with 16 new drugs expected by 2029, according to the report. Analysts added that this could result in an additional $70 billion in the GLP-1 market by 2031.
These new entrants are expected to...
Today's Sponsors
Today's Sponsor